Gliosarcoma Clinical and Molecular Characteristics

Gliosarcoma is a rare, highly aggressive primary brain tumour accounting for a small fraction of glioblastoma-grade lesions. It exhibits a characteristic biphasic growth pattern, with intermingled glial and mesenchymal components. Clinically, it most often presents in middle-aged adults with headaches, focal neurological deficits and seizure activity. Radiologically, these tumours may show heterogeneous contrast enhancement and peripheral oedema. Histopathologically, the glial component is typically IDH-wildtype and shares features with glioblastoma, while the sarcomatous component comprises spindle-shaped cells embedded in a collagen-rich matrix. Molecular profiling reveals frequent TERT promoter mutations, PTEN and TP53 alterations, and dysregulation of PI3K/Akt and RAS/MAPK pathways. Compared with conventional glioblastoma, gliosarcoma often exhibits higher rates of PTEN loss, CDKN2A/B deletion and distinct patterns of collagen gene expression. Methylation of the MGMT promoter is less common, reflecting relative chemoresistance. Standard management involves maximal safe surgical resection followed by radiotherapy with concomitant and adjuvant temozolomide, yet overall survival remains poor, typically under 15 months. Rare occurrences of extracranial metastases and treatment-related hypermutation underscore the need for improved molecularly guided interventions.

Research from Nature Portfolio

Comprehensive analysis of a multicentre genomics database has mapped the landscape of somatic alterations in gliosarcoma, identifying nineteen recurrently mutated genes. While many alterations overlap those found in glioblastoma and soft tissue sarcoma, several—such as BRAF mutations—appear distinct and potentially actionable, suggesting tumour classification and trial eligibility should reflect these unique signatures. Separately, a large population-based study has developed and internally validated a prognostic nomogram for primary gliosarcoma, incorporating age, tumour size, metastatic status and receipt of adjuvant chemotherapy. This tool demonstrated good calibration for one-year survival predictions and offers a framework for personalised post-surgical risk stratification and therapeutic decision-making.

Gliosarcoma Clinical and Molecular Characteristics publication trend

The graph below shows the total number of articles in gliosarcoma clinical and molecular characteristics across all publications each year (not limited to Nature Index journals).

Technical terms

Biphasic growth pattern: Coexistence of glial and sarcomatous tissue within the same tumour.

Hypermutated phenotype: High burden of somatic mutations, often due to mismatch repair defects.

MGMT promoter methylation: Epigenetic silencing of the DNA repair gene MGMT, influencing response to alkylating agents.

Epithelial-to-mesenchymal transition: Biological process in which cells gain migratory and invasive properties.

Radiomics: Extraction of quantitative features from medical imaging for diagnostic or prognostic modelling.

References

1. Hypermutated phenotype in gliosarcoma of the spinal cord. npj Precision Oncology (2021).
2. Clinical Characteristics of Gliosarcoma and Outcomes From Standardized Treatment Relative to Conventional Glioblastoma. Frontiers in Oncology (2019).
3. Gliosarcoma Is Driven by Alterations in PI3K/Akt, RAS/MAPK Pathways and Characterized by Collagen Gene Expression Signature. Cancers (2019).
4. Genomic landscape of gliosarcoma: distinguishing features and targetable alterations. Scientific Reports (2021).
5. Clinical characteristics and disease-specific prognostic nomogram for primary gliosarcoma: a SEER population-based analysis. Scientific Reports (2019).
6. Machine Learning-Based Analysis of Magnetic Resonance Radiomics for the Classification of Gliosarcoma and Glioblastoma. Frontiers in Oncology (2021).
7. Evaluating Surgical Resection Extent and Adjuvant Therapy in the Management of Gliosarcoma. Frontiers in Oncology (2020).